Oragenics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. This development-stage biotechnology company reported for the three months ended March 31, 2024. Since December 2023, its principal focus has been ONP-002, an intranasal candidate for mild traumatic brain injury (concussion). COVID-19 vaccine and lantibiotic research programs are inactive or paused while the company focuses limited resources on ONP-002.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Revenue | No grant revenue | $17,024 grant revenue |
| Research and development expense | $663,414 | $1,672,576; down 60.3% |
| General and administrative expense | $1,796,689 | $1,249,263; up 43.8% |
| Operating loss | $2,460,103 | $2,904,815 |
| Net loss | $2,450,833 | $2,844,837 |
| Basic and diluted loss per share | $0.70 | $1.41 |
| Net cash used in operating activities | $3,064,249 in the cash flow statement | $2,108,695 |
Interest income was $19,235, interest expense was $7,085, and total other income, net, was $9,270. No income tax benefit was recorded. Profit margins are not meaningful given the absence of material operating revenue and continuing losses.
At March 31, 2024, cash and cash equivalents were $2,071,989, versus $3,483,501 at year-end 2023. Current assets were $2,443,201 and current liabilities were $908,686, yielding reported working capital of $1,534,515. Total assets were $3,533,951; total liabilities were $908,686; and shareholders’ equity was $2,625,265. Short-term notes payable were $126,840, down from $312,703 at year-end; the remaining balance related to insurance financing at 9.55% interest. No long-term debt was reported.
Operating cash use was partly funded by a March public offering: 1.4 million common shares sold at $1.50 per share generated $2.1 million gross and $1,838,600 net proceeds reported in financing cash flows. Cash from financing activities was $1,652,737, including note repayments. Common shares outstanding rose from 3,080,693 at December 31, 2023 to 4,480,693 at March 31, 2024.
Material changes versus the prior period
- R&D expense declined by $1,009,162, primarily as spending shifted away from the COVID vaccine and lantibiotic programs to ONP-002. Management attributed approximately $0.5 million of Q1 2024 R&D to ONP-002 and approximately $0.1 million to the vaccine candidate.
- G&A expense increased by approximately $547,426, with higher accounting, investor-relations, salary and bonus, consulting, and insurance costs.
- Net loss narrowed by $394,004, while cash used in operations increased year over year. The filing attributes the cash-use increase to net loss adjustments and movements in operating assets and liabilities.
- The March offering increased common shares outstanding by 1.4 million. The company also issued 70,000 warrants at a $1.88 exercise price as part of the offering-related arrangements.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: The company reports recurring losses and negative operating cash flows and states that substantial doubt exists about its ability to continue as a going concern. Management says current resources are expected to fund the operating plan only through the third quarter of 2024; additional capital is required, with no committed financing source or assurance of availability. Cost reductions include staffing and R&D cuts and termination of the Tampa office lease.
- ONP-002 development: Phase 1 in healthy volunteers was completed and described as safe and well tolerated. Management estimated a Phase 2a start in Australia in Q2/Q3 2024, a Phase 2b start in Q4 2024, and a Phase 3 start in Q4 2026. These are estimates subject to funding, technical risks, and regulatory approvals; the filing describes plans to pursue an FDA IND and further clinical testing.
- NYSE American listing: On April 18, 2024, the company received notice that it did not meet continued listing equity standards. It was required to submit a compliance plan by May 18, 2024, with a stated target to regain compliance by October 18, 2025. The shares were to remain listed during the review period, with a “.BC” below-compliance designation. Delisting could impair share liquidity and access to capital.
- Litigation: Ladenburg Thalmann demanded a $2.5 million fee related to the Odyssey asset purchase. Oragenics disputes the claim and initiated FINRA arbitration; Ladenburg also filed a federal complaint. The company intends to defend itself, but states that an unfavorable outcome could materially affect its business and financial position. The filing does not provide a clear estimate of potential loss.
- Dilution and other risks: Future financing may dilute existing shareholders or involve securities with senior rights. The filing says conversion of Odyssey Series F and Series A/B preferred shares could result in up to 7,511,220 additional common shares. The company’s development plans depend on securing funding; failure could delay or curtail trials and other programs.
- Program decisions: Vaccine and lantibiotic work remains paused pending resources. Management is evaluating alternatives for these assets, which could include a sale, spin-off, financing, combination, or winding down activities.
Important facts for investors to verify
- Reconcile operating cash used: the cash flow statement reports $3,064,249, while MD&A reports $3,062,249 in one passage and $3,062,249 in another liquidity discussion; the filing text does not provide a clear reconciled value.
- Clarify the runway statements: the filing generally says cash supports operations through Q3 2024, but a risk-factor passage refers to substantial doubt beyond June 2024.
- Check actual progress on the NYSE American compliance plan, its acceptance and milestones, and whether additional financing restores required shareholders’ equity.
- Track whether ONP-002 clinical milestones proceed on the stated schedule and whether financing and regulatory steps support the plans.
- Monitor the Ladenburg dispute and any changes in the company’s assessment of potential exposure.